Kailera Therapeutics, Inc. Common Stock (KLRA)vsModerna Inc (MRNA)
KLRA
Kailera Therapeutics, Inc. Common Stock
$10.39
-5.80%
HEALTHCARE · Cap: $1.55B
MRNA
Moderna Inc
$190.01
+0.57%
HEALTHCARE · Cap: $69.04B
Smart Verdict
WallStSmart Research — data-driven comparison
KLRA leads profitability with a 0.0% profit margin vs -141.4%. KLRA earns a higher WallStSmart Score of 31/100 (F).
KLRA
Avoid31
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for KLRA.
Margin of Safety
+69.9%
Fair Value
$134.59
Current Price
$190.01
$55.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 11.2x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : KLRA
The strongest argument for KLRA centers on Price/Book, Debt/Equity.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : KLRA
The primary concerns for KLRA are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
KLRA profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
KLRA generates stronger free cash flow (-78M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
KLRA scores higher overall (31/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kailera Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Kailera Therapeutics, Inc. is a cutting-edge biotechnology company dedicated to developing innovative gene therapies for rare genetic diseases, addressing critical unmet medical needs. Utilizing its proprietary platform, Kailera aims to enhance the precision and effectiveness of therapeutic interventions across various genetic disorders. Backed by a strong intellectual property portfolio and strategic collaborations with premier research institutions, the company is poised to emerge as a leader in the gene therapy sector. As it progresses with a promising pipeline of products, Kailera Therapeutics is committed to delivering long-term value for its investors while significantly improving patient outcomes.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?